Business
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".
About this update from Volitionrx Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Targets $36 Billion TAM in Early Cancer Detection and MRD. ","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Company in active discussions with global diagnostic leaders to accelerate commercialization.","length":93,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":151,"olType":false},{"type":"text","content":"HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".","length":506,"tagName":"p"},{"id":"R11jftp4Vcw","subtype":"videoIframe","type":"youtube","url":"https://www.youtube.com/embed/R11jftp4Vcw","width":560,"height":315,"anchorId":"0e947e66-d158-5d25-881a-58a0d6ae8667"},{"type":"text","content":"The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.","length":315,"tagName":"p"},{"type":"text","content":"Dr Jake Micallef, Chief Scientific Officer, Volition commented:","length":63,"tagName":"p"},{"type":"text","content":""Distinguishing cancer derived plasma DNA from healthy DNA when the two are mixed is problematic. When the cancer DNA makes up 1% or less of the total DNA it is extremely problematic. Moreover, DNA from cancer and healthy cells has the same double helix structure and has never before been separated chemically.","length":316,"tagName":"p"},{"type":"text","content":""Our manuscript, submitted in November and previously announced in December 2025, described a new liquid biopsy chemistry for isolating CTCF-DNA from plasma. Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer pati...